Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

ESAM is functionally involved in the activity of cancer stem-like cells in human acute myeloid leukemia

Henyun Shi, Yosuke Matsuoka, Jun Nakayama et al. Nov 03, 2025 pp. 3476-3476 10.1182/blood-2025-3476

Abstract Despite major advances in molecularly targeted therapies for hematologic malignancies such as CML and malignant lymphoma, effective...

Gut microbiome structure prior to neoadjuvant chemoradiotherapy predicts risk of myelosuppression in rectal cancer patients

Zhenhui Chen, Lu Yu, Jian Xie et al. Nov 03, 2025 pp. 6556-6556 10.1182/blood-2025-6556

Abstract Background The gut microbiome plays a significant role in colorectal cancer development and treatment response. Neoadjuvant chemora...

Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States

Yun Kyoung Tiger, Roshan Asrani, Graham Wehmeyer et al. Nov 03, 2025 pp. 1956-1956 10.1182/blood-2025-1956

Abstract Background: Glofit, a CD20/CD3 bispecific antibody, has shown efficacy in prospective trials, including the Phase III STARGLO study...

Lipid metabolic reprogramming mediated by YTHDF3 deficiency underlies immunotherapy resistance in extranodal NK/T-cell lymphoma

Jinni Wang, Qingqing Cai, Wenlong Zhong et al. Nov 03, 2025 pp. 5335-5335 10.1182/blood-2025-5335

Abstract Background: Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive non-Hodgkin lymphoma subtype. Despite improved outcomes with imm...

AAV gene therapy in hemophilia B shows robust bleeding reduction and variable factor IX expression: A bayesian meta-analysis of randomized controlled trials

Gowarishankar Palaniswamy, Moitreyo Pandit, Dhruvi Pathak et al. Nov 03, 2025 pp. 4852-4852 10.1182/blood-2025-4852

Abstract Introduction Hemophilia B, a congenital X-linked bleeding disorder caused by factor IX (FIX) deficiency, poses significant challeng...

Interleukin-12 and TNFα signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms

Tyler Parsons, Aishwarya Krishnan, Infencia Xavier Raj et al. Nov 03, 2025 pp. 5538-5538 10.1182/blood-2025-5538

Abstract Progression from chronic phase myeloproliferative neoplasm (MPN) to secondary acute myeloid leukemia (sAML) is a poorly understood,...

HSV-1 infection as a rare trigger of methotrexate toxicity: A diagnostic and therapeutic challenge

Danyal Butt, Faisal Shariff, Marina Khan et al. Nov 03, 2025 pp. 6738-6738 10.1182/blood-2025-6738

Abstract Introduction: We present a novel case of severe pancytopenia in a 63-year-old woman receiving low-dose methotre...

Triptonide and bortezomib synergistically inhibit multiple myeloma by enhancing DNA damage through blocking TRIP13-mediated DNA repair

Fen He, Hongyan Zhao, Maoyou Lu et al. Nov 03, 2025 pp. 2165-2165 10.1182/blood-2025-2165

Abstract Background: Multiple myeloma (MM) is a malignant neoplasm of plasma cells. Clinically, the proteasome inhibitor bortezomib (BTZ) in...

A retrospective survival outcomes analysis of acute erythroid leukemia patients treated with upfront 7+3 induction chemotherapy versus hypomethylating agents with venetoclax utilizing real-world data

Mohamed Zakee Mohamed Jiffry, Devashish Desai, Bhaskara Madhira et al. Nov 03, 2025 pp. 1669-1669 10.1182/blood-2025-1669

Abstract Background: Acute erythroid leukemia (AEL) is considered a rare and aggressive subtype of acute myeloid leukemia (AML). There is so...

B-lineage acute lymphoblastic leukaemia disrupts a LepR+ bone marrow stromal niche which is critical for CAR-T cell persistence

Aideen O'Neill, Constandina Pospori, Elisa Armbrecht et al. Nov 03, 2025 pp. 4118-4118 10.1182/blood-2025-4118

Abstract B-lineage acute lymphoblastic leukaemia (B-ALL) is an aggressive haematological malignancy with high treatment failure rates. Whils...

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

Amanda Johnson, Yuxin Zhao, Xi Qiao et al. Nov 03, 2025 pp. 511-511 10.1182/blood-2025-511

Abstract HCT is a well-established standard therapy for children and young adults (CYA) with very high-risk/relapsed B-ALL. Recent studies h...

Artificial intelligence/machine learning-based risk prediction model guiding individualized interventions to improve outcomes for patients with multiple myeloma

Stuart Sommers, Chunlei Zheng, June Corrigan et al. Nov 03, 2025 pp. 4589-4589 10.1182/blood-2025-4589

Abstract Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, with approximately 32,000 new cases an...

Mitochondrial RNA pseudouridine reprograms metabolism and induces immunosuppression in myeloid leukemia

Honghai Zhang, Xueer Wang, Lei Dong et al. Nov 03, 2025 pp. 211-211 10.1182/blood-2025-211

Abstract Pseudouridine (Ψ) is the most prevalent RNA modification in human cells. Although Ψ was among the first post-transcriptional modifi...

Dual-function engineered bacteria remodel AML tumor microenvironment via IL-12 delivery and adenosine depletion to sustain NK cell immunity

Stephanie Sendker, Shaobo Yang, Anna Clara Bader et al. Nov 03, 2025 pp. 5912-5912 10.1182/blood-2025-5912

Abstract Background Cellular immunotherapy has revolutionized cancer treatment. Yet its efficacy in acute myeloid leukemia (AML) remains lim...

Large language model for abstraction of CAR-T therapy toxicities data

Kayla Joseph, Andre De Menezes Silva Corraes, Emmanuel Contreras Guzman et al. Nov 03, 2025 pp. 6139-6139 10.1182/blood-2025-6139

Abstract Introduction: Reporting patient outcomes by CAR-T treatment centers is part of the accreditation requirement un...

Expanding the boundaries of CAR T-cell therapy: Implementation of an outpatient-at-home (OATH) model

Beatriz Merchan Muñoz, Alexandra Martinez-Roca, Nuria Ballestar et al. Nov 03, 2025 pp. 6192-6192 10.1182/blood-2025-6192

Abstract Background: CAR-T cell immunotherapy represents a major advancement in the treatment of relapsed/refractory (R/R) hematologic malig...

Microbiota-derived 1,5-pentanediamine attenuates CD19 CAR-T function

Rubing Zheng, Xi Ming, delian Zhou et al. Nov 03, 2025 pp. 7619-7619 10.1182/blood-2025-7619

Abstract Background: Previous studies indicate that bacteremia may compromise CAR-T cell therapy efficacy. However, it remains unclear wheth...

A potential drug to overcome the venetoclax resistance challenge in AML: Mitoxantrone hydrochloride liposome

Wenxiang Ren, Xiaobo Tian, Yanni Ma et al. Nov 03, 2025 pp. 6954-6954 10.1182/blood-2025-6954

Abstract The venetoclax combined with azacitidine regimen has greatly improved the prognosis of acute myeloid leukemia (AML). However, appro...

A novel conditioning regimen combining selinexor with melphalan  Improves Survival in Patients with multiple myeloma:a prospective study

Liangliang Ma, Jingping Zhang, Xiaoqing Chen et al. Nov 03, 2025 pp. 5837-5837 10.1182/blood-2025-5837

Abstract Background: High-dose melphalan followed by autologous hematopoietic stem cell transplantation (ASCT) remains the standard consolid...

Outcomes for black persons with multiple myeloma: A national retrospective trend analysis from 2015 to 2022

Vineet Polineni, Danielle Thor, Tony Elias et al. Nov 03, 2025 pp. 2821-2821 10.1182/blood-2025-2821

Abstract Introduction: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at...

Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model

Yuhua Wan, Dexian Quan, Shulin Yang et al. Nov 03, 2025 pp. 5847-5847 10.1182/blood-2025-5847

Abstract Background: Two BCMA-directed CAR-T cell products, Idecabtagene vicleucel (ide-cel) and Ciltacabtagene autoleucel (cilta-cel), have...

Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies

Qian Jiang, Huafeng Wang, Xingli Zhao et al. Nov 03, 2025 pp. 3417-3417 10.1182/blood-2025-3417

Abstract Background :Venetoclax has been approved for the treatment of newly diagnosed acute myeloid leukemia (AML) in elderly or unfit patie...

Steroid-toxicity in newly diagnosed patients with multiple myeloma treated with a limited dexamethasone regimen; Results from the nmsg rest study

Lene Kongsgaard Nielsen, Tine Rosenberg, Andreas Kristian Pedersen et al. Nov 03, 2025 pp. 2785-2785 10.1182/blood-2025-2785

Abstract Introduction: For decades corticosteroids (steroids) have been essential in treating patients with multiple myeloma (MM). However,...

Rethinking neutropenia thresholds: Ethnicity-specific distributions and mortality associations in the United States adult population using national health and nutrition examination survey 2017–2018

Tiantian Zhang, Simo Du, Pei-Lun Kuo et al. Nov 03, 2025 pp. 2978-2978 10.1182/blood-2025-2978

Abstract Introduction Absolute neutrophil count (ANC) is widely used to define neutropenia, with an ANC <1500/μL serving as a univers...

High-dose cryopreserved bone marrow from deceased donors may reduce relapse in HLA-mismatched allogeneic transplantation: Day 180 post-transplant HOPE update

Sagar Munjal, Muneer Abidi, Jeremy Pantin et al. Nov 03, 2025 pp. 5976-5976 10.1182/blood-2025-5976

Abstract Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment for many hematologic malignancies. Hist...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page